Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) EVP Stuart A. Arbuckle sold 1,208 shares of the firm’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $90.00, for a total transaction of $108,720.00. Following the completion of the sale, the executive vice president now owns 113,358 shares of the company’s stock, valued at approximately $10,202,220. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) opened at 93.06 on Wednesday. Vertex Pharmaceuticals Inc. has a 1-year low of $73.31 and a 1-year high of $134.71. The firm’s 50-day moving average is $83.61 and its 200 day moving average is $89.62. The company’s market cap is $23.08 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Tuesday, October 25th. The pharmaceutical company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.18 by $0.02. Vertex Pharmaceuticals had a negative net margin of 13.45% and a negative return on equity of 5.31%. The company had revenue of $413.78 million for the quarter, compared to analyst estimates of $423.53 million. During the same quarter last year, the business earned ($0.13) EPS. The company’s revenue for the quarter was up 33.6% on a year-over-year basis. Equities analysts expect that Vertex Pharmaceuticals Inc. will post $0.78 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Institutional investors have recently made changes to their positions in the stock. Capital World Investors increased its position in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company’s stock valued at $1,944,119,000 after buying an additional 599,586 shares during the period. FMR LLC increased its position in shares of Vertex Pharmaceuticals by 46.9% in the second quarter. FMR LLC now owns 22,227,104 shares of the pharmaceutical company’s stock valued at $1,911,975,000 after buying an additional 7,092,351 shares during the period. Vanguard Group Inc. increased its position in shares of Vertex Pharmaceuticals by 2.2% in the second quarter. Vanguard Group Inc. now owns 15,265,175 shares of the pharmaceutical company’s stock valued at $1,313,110,000 after buying an additional 329,337 shares during the period. JPMorgan Chase & Co. increased its position in shares of Vertex Pharmaceuticals by 4.2% in the second quarter. JPMorgan Chase & Co. now owns 12,173,439 shares of the pharmaceutical company’s stock valued at $1,047,161,000 after buying an additional 485,112 shares during the period. Finally, State Street Corp increased its position in shares of Vertex Pharmaceuticals by 0.4% in the second quarter. State Street Corp now owns 9,825,708 shares of the pharmaceutical company’s stock valued at $845,214,000 after buying an additional 35,700 shares during the period. Institutional investors own 96.20% of the company’s stock.

VRTX has been the subject of several recent analyst reports. RBC Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Saturday, October 1st. Leerink Swann set a $112.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, September 17th. Cowen and Company reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, July 28th. Credit Suisse Group AG set a $110.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, September 28th. Finally, Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, October 31st. Fourteen investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $108.63.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.